Use of in vivo animal models to assess pharmacokinetic drug-drug interactions

Pharmaceutical Research

Volumn 27, Issue 9, 2010, Pages 1772-1787

  Tang, Cuyue ^a   Prueksaritanont, Thomayant ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

animal models; drug transporters; drug drug interactions; metabolizing enzymes

Indexed keywords

4 AMINOHIPPURIC ACID; ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 3A; DEXAMPHETAMINE; DICLOFENAC; DIGOXIN; ELACRIDAR; ERYTHROMYCIN; FAMOTIDINE; INDINAVIR; KETOCONAZOLE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; NIFEDIPINE; PROBENECID; QUINIDINE; RIFAMPICIN; SULFAPHENAZOLE; TARIQUIDAR; TEMOCAPRILAT; TIENILIC ACID; UNINDEXED DRUG; VERAPAMIL; XENOBIOTIC AGENT;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG UPTAKE; ENZYME METABOLISM; ENZYME SPECIFICITY; GLOMERULUS FILTRATION RATE; HUMAN; HYDROXYLATION; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; KIDNEY CLEARANCE; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; STOMACH EMPTYING; STOMACH PH;

ANIMALS; DRUG DISCOVERY; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, ANIMAL; SPECIES SPECIFICITY;

EID: 77955469303     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0157-z     Document Type: Review

References (103)

1. RJ Weaver 2001 Assessment of drug-drug interactions: concepts and approaches Xenobiotica 31 499 538 1:CAS:528:DC%2BD3MXmvF2lt78%3D 11569524
2. PD Worboys DJ Carlile 2001 Implications and consequences of enzyme induction on preclinical and clinical drug development Xenobiotica 31 539 56 1:CAS:528:DC%2BD3MXmvF2lt7w%3D 11569525
3. JB Houston A Galetin 2003 Progress towards prediction of human pharmacokinetic parameters from in vitro technologies Drug Metab Rev 35 393 415 1:CAS:528:DC%2BD3sXps1ygsL8%3D 14705868
4. K Ito HS Brown JB Houston 2004 Database analyses for the prediction of in vivo drug-drug interactions from in vitro data Br J Clin Pharmacol 57 473 86 1:CAS:528:DC%2BD2cXjslGmsb8%3D 15025746
5. T Kanazu Y Yamaguchi N Okamura T Baba M Koike 2004 Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans Xenobiotica 34 391 402 1:CAS:528:DC%2BD2cXmtVyhsb0%3D 15370956 (Pubitemid 38901450)
6. T Prueksaritanont R Subramanian X Fang B Ma Y Qiu JH Lin PG Pearson TA Baillie 2002 Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization Drug Metab Dispos 30 505 12 1:CAS:528: DC%2BD38Xjt12ls74%3D 11950779
7. JH Lin 2008 Applications and limitations of genetically modified mouse models in drug discovery and development Curr Drug Metab 9 419 38 1:CAS:528:DC%2BD1cXotF2ntLk%3D 18537578
8. JH Lin 1995 Species similarities and differences in pharmacokinetics Drug Metab Dispos 23 1008 21 1:CAS:528:DyaK2MXovFGksbw%3D 8654187
9. H Lennernäs 2007 Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo Adv Drug Deliv Rev 59 1103 20 17900749
10. KA Lentz M Quitko DG Morgan JE Grace C Gleason PH Marathe 2007 Development and validation of a preclinical food effect model J Pharm Sci 96 459 72 1:CAS:528:DC%2BD2sXhsFGmur4%3D 17075867
11. SK Paulson MB Vaughn SM Jessen Y Lawal CJ Gresk B Yan TJ Maziasz CS Cook A Karim 2001 Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption J Pharmacol Exp Ther 297 638 45 1:CAS:528:DC%2BD3MXjt1Wlsbw%3D 11303053
12. S Conrad A Viertelhaus A Orzechowski J Hoogstraate K Gjellan D Schrenk HM Kauffmann 2001 Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1 Toxicology 156 81 91 1:CAS:528: DC%2BD3MXntl2lsA%3D%3D 11164610
13. S Berggren C Gall N Wollnitz M Ekelund U Karlbom J Hoogstraate D Schrenk H Lennernäs 2007 Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine Mol Pharm 4 252 7 1:CAS:528:DC%2BD2sXhtVOmtL8%3D 17263554
14. RC Schnell TS Miya 1970 Altered absorption of drugs from the rat small intestine by carbonic anhydrase inhibition J Pharmacol Exp Ther 174 177 84 1:CAS:528:DyaE3cXkslGiu70%3D 4988984
15. WL Hayton G Levy 1971 Effect of SKF 525-A on drug absorption in rats Life Sci I 10 691 7 1:CAS:528:DyaE3MXkvFOit7w%3D 5556757
16. EL McConnell AW Basit S Murdan 2008 Measurements of rat and mouse gastrointestinal pH fluid and lymphoid tissue, and implications for in-vivo experiments J Pharm Pharmacol 60 63 70 1:CAS:528:DC%2BD1cXhsV2ksbY%3D 18088506
17. X Cao ST Gibbs L Fang HA Miller CP Landowski HC Shin H Lennernas Y Zhong GL Amidon LX Yu D Sun 2006 Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model Pharm Res 23 1675 86 1:CAS:528:DC%2BD28XnvVyms7c%3D 16841194
18. Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm. 2009 Nov 26. doi: 10.1016/j.ijpharm.2009.11.021.
19. K Ikegami K Tagawa S Narisawa T Osawa 2003 Suitability of the cynomolgus monkey as an animal model for drug absorption studies of oral dosage forms from the viewpoint of gastrointestinal physiology Biol Pharm Bull 26 1442 7 1:CAS:528:DC%2BD3sXotlGrs7Y%3D 14519952
20. T Akabane K Tabata K Kadono S Sakuda S Terashita T Teramura 2010 A Comparison of Pharmacokinetics Between Humans and Monkeys Drug Metab Dispos 38 308 16 1:CAS:528:DC%2BC3cXhsVSmsrk%3D 19910513
21. M Takahashi T Washio N Suzuki K Igeta S Yamashita 2009 The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans J Pharm Sci 98 4343 53 1:CAS:528: DC%2BD1MXhtF2qtLnL 19230019
22. M Takahashi T Washio N Suzuki K Igeta Y Fujii M Hayashi Y Shirasaka S Yamashita 2008 Characterization of gastrointestinal drug absorption in cynomolgus monkeys Mol Pharmaceut 5 340 8 1:CAS:528:DC%2BD1cXhsVKks7c%3D
23. CQ Xia G Xiao N Liu S Pimprale L Fox CJ Patten CL Crespi G Miwa LS Gan 2006 Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays Mol Pharm 3 78 86 1:CAS:528:DC%2BD2MXhtlajtrnP 16686372
24. M Katoh N Suzuyama T Takeuchi S Yoshitomi S Asahi T Yokoi 2006 Kinetic analyses for species differences in P-glycoprotein-mediated drug transport J Pharm Sci 95 2673 83 1:CAS:528:DC%2BD28XhtlSis7%2FK 16892207
25. N Suzuyama M Katoh T Takeuchi S Yoshitomi T Higuchi S Asashi T Yokoi 2007 Species differences of inhibitory effects on P-glycoprotein-mediated drug transport J Pharm Sci 96 1609 18 1:CAS:528:DC%2BD2sXmt1CisL8%3D 17094122
26. Y Lai 2009 Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion Expert Opin Drug Metab Toxicol 5 1175 87 1:CAS:528:DC%2BD1MXhtFCgsrfP 19611403
27. H Jin L Di 2008 Permeability-in vitro assays for assessing drug transporter activity Curr Drug Metab 9 911 20 1:CAS:528:DC%2BD1MXivF2nsbs%3D 18991588
28. W Löscher H Potschka 2005 Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2 86 98 15717060
29. A Doran RS Obach BJ Smith NA Hosea S Becker E Callegari C Chen X Chen E Choo J Cianfrogna LM Cox JP Gibbs MA Gibbs H Hatch CE Hop IN Kasman J Laperle J Liu X Liu M Logman D Maclin FM Nedza F Nelson E Olson S Rahematpura D Raunig S Rogers K Schmidt DK Spracklin M Szewc M Troutman E Tseng M Tu JW Van Deusen K Venkatakrishnan G Walens EQ Wang D Wong AS Yasgar C Zhang 2005 The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab Dispos 33 165 74 1:CAS:528:DC%2BD2MXltlentw%3D%3D 15502009
30. EM Kemper AE van Zandbergen C Cleypool HA Mos W Boogerd JH Beijnen O van Tellingen 2003 Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein Clin Cancer Res 9 2849 55 1:CAS:528:DC%2BD3sXlt1yrsbo%3D 12855665
31. T Takeuchi S Yoshitomi T Higuchi K Ikemoto S Niwa T Ebihara M Katoh T Yokoi S Asahi 2006 Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1 Pharm Res 23 1460 72 1:CAS:528:DC%2BD28XmsFOmur0%3D 16779700
32. IW Kim C Booth-Genthe SV Ambudkar 2008 Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1) Mini Rev Med Chem 8 193 200 1:CAS:528:DC%2BD1cXivFalsro%3D 18336339
33. C Tang Y Kuo NT Pudvah JD Ellis MS Michener M Egbertson SL Graham JJ Cook JH Hochman T Prueksaritanont 2009 Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys Biochem Pharmacol 78 642 7 1:CAS:528:DC%2BD1MXpt1KlsLw%3D 19481060
34. SS Zoghbi JS Liow F Yasuno J Hong E Tuan N Lazarova RL Gladding VW Pike RB Innis 2008 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux Nucl Med 49 649 56 1:CAS:528:DC%2BD1cXltl2gtb8%3D
35. S Eyal FS Chung M Muzi JM Link DA Mankoff A Kaddoumi F O'Sullivan MF Hebert JD Unadkat 2009 Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate J Nucl Med 50 798 806 1:CAS:528:DC%2BD1MXmtV2hsro%3D 19403878
36. P Hsiao T Bui R Ho JD Unadkat 2008 In Vitro to In Vivo Prediction of Pglycoprotein Based Drug Interactions at the Human and Rodent Blood-Brain Barrier Drug Metab Dispos 36 481 4 1:CAS:528:DC%2BD1cXjt1arsL4%3D 18057117
37. S Eyal P Hsiao JD Unadkat 2009 Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123 80 104 1:CAS:528: DC%2BD1MXms1ahsb0%3D 19393264
38. P Li GJ Wang TA Robertson MS Roberts 2009 Liver transporters in hepatic drug disposition: an update Curr Drug Metab 10 482 98 1:CAS:528: DC%2BD1MXhtVGhtbzO 19689245
39. A Grover LZ Benet 2009 Effects of drug transporters on volume of distribution AAPS J 11 250 61 1:CAS:528:DC%2BD1MXhtVWqs7rP 19399628
40. LI Harrison M Gibaldi 1976 Pharmacokinetics of digoxin in the rat Drug Metab Dispos 4 88 93 1:CAS:528:DyaE28XhtlSjurw%3D 3407
41. JL Lam SB Shugarts H Okochi LZ Benet 2006 Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism J Pharmacol Exp Ther 319 864 70 1:CAS:528:DC%2BD28XhtFOkurjI 16905688
42. YY Lau Y Huang L Frassetto LZ Benet 2007 Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers Clin Pharmacol Ther 81 194 204 1:CAS:528:DC%2BD2sXisFyrtLY%3D 17192770
43. FP Guengerich 1997 Role of cytochrome P450 enzymes in drug-drug interactions Adv Pharmacol 43 7 35 1:CAS:528:DyaK2sXnt1aks7Y%3D 9342171
44. GK Dresser JD Spence DG Bailey 2000 Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 41 57 1:CAS:528:DC%2BD3cXhtV2kurw%3D 10668858
45. A Galetin M Gertz JB Houston 2008 Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions Expert Opin Drug Metab Toxicol 4 909 22 1:CAS:528:DC%2BD1cXos1ChtbY%3D 18624679
46. JE Sharer LA Shipley MR Vandenbranden SN Binkley SA Wrighton 1995 Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey Drug Metab Dispos 23 1231 41 1:CAS:528:DyaK2MXpsFKmsro%3D 8591724
47. T Prueksaritanont LM Gorham JH Hochman L Tran KP Vyas 1996 Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells Drug Metab Dispos 24 634 42 1:CAS:528:DyaK28Xjs1Crt7w%3D 8781778
48. M Martignoni GMM Groothuis R de Kanter 2006 Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction Expert Op Drug Metab Toxico 2 875 94 1:CAS:528:DC%2BD28Xht1eks7nJ
49. B Carr R Norcross YL Fang P Lu AD Rodrigues MG Shou T Rushmore C Booth-Genthe 2007 Characterization of the rhesus monkey CYP3A64 enzyme: Species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes Drug Metab Dispos 34 1703 12
50. C Tang Y Fang C Booth-Genthe Y Kuo SD Kuduk TH Rushmore BA Carr 2007 Diclofenac hydroxylation in monkeys: efficiency, regioselectivity, and response to inhibitors Biochem Pharmacol 73 880 90 1:CAS:528:DC%2BD2sXhvVOqsro%3D 17223083
51. VA Eagling JF Tjia DJ Back 1998 Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes Br J Clin Pharmacol 45 107 14 1:CAS:528:DyaK1cXhtFSkt7c%3D 9491822
52. DC Swinney 1990 Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat Drug Metab Dispos 18 859 65 1:CAS:528:DyaK3MXhslOjtw%3D%3D 1981529
53. A Ogasawara I Negishi K Kozakai T Kume 2009 In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys Drug Metab Dispos 37 2127 36 1:CAS:528:DC%2BD1MXhtlOqtbbJ 19704026
54. W Tang RA Stearns RW Wang RR Miller Q Chen J Ngui RK Bakshi RP Nargund DC Dean TA Baillie 2008 Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists Xenobiotica 38 1437 51 1:CAS:528:DC%2BD1cXhtlens7vP 18841517
55. T Prueksaritanont Y Kuo C Tang C Li Y Qiu B Lu K Strong-Basalyga K Richards B Carr JH Lin 2006 In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: A preclinical approach for CYP3A-mediated drug interaction studies Drug Metab Dispos 34 1546 55 1:CAS:528: DC%2BD28Xpt1SksLw%3D 16782766
56. S Kim JE Dinchuk MN Anthony T Orcutt ME Zoeckler MB Sauer KW Mosure R Vuppugalla JE Grace Jr J Simmermacher HA Dulac J Pizzano M Sinz 2010 Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction Drug Metab Dispos 38 16 24 1:CAS:528:DC%2BD1MXhs1aru7fF 19833845
57. Y Nishibe M Wakabayashi T Harauchi K Ohno 1998 Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver Xenobiotica 28 549 57 1:CAS:528:DyaK1cXks1Ggs7k%3D 9667078
58. RA Graham A Downey D Mudra L Krueger K Carroll C Chengelis A Madan A Parkinson 2002 In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs Drug Metab Dispos 30 1206 13 1:CAS:528:DC%2BD38XotFykurY%3D 12386126
59. RA Graham LO Tyler WL Krol IS Silver LO Webster P Clark L Chen T Banks EL LeCluyse 2006 Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes J Biochem Mol Toxicol 20 2 69 78 1:CAS:528:DC%2BD28Xjs12jtLg%3D 16615094
60. Y Kyokawa Y Nishibe M Wakabayashi T Harauchi T Maruyama T Baba K Ohno 2001 Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs Chem Biol Interact 134 291 305 1:CAS:528:DC%2BD3MXjtFCrtbw%3D 11336977
61. GG Gibson NJ Plant KE Swales A Ayrton W El-Sankary 2002 Receptor-dependent transcriptional activation of cytochrome P450 3A genes: induction, mechanisms, species differences and interindividual variations in man Xenobiotica 32 165 206 1:CAS:528:DC%2BD38XivFGhtL0%3D 11958559
62. H Komura M Iwaki 2008 Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates J Pharm Sci 97 1775 800 1:CAS:528:DC%2BD1cXltlenu7Y%3D 17853429
63. K Iwasaki Y Uno 2009 Cynomolgus monkey CYPs: a comparison with human CYPs Xenobiotica 39 578 81 1:CAS:528:DC%2BD1MXovVCisrg%3D 19622000
64. Y Uno S Hiroko U Shotaro K Takayuki M Kiyomi N Chika K Go K Tetsuya N Ryoichi 2006 A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism Mol Pharmacol 70 477 86 1:CAS:528:DC%2BD28XnslOqu7Y%3D 16648389
65. C Tang BA Carr F Poignant B Ma S Polsky-Fisher Y Kuo K Strong-Basalyga A Norcross K Richards R Eisenhandler E Carlini C Ng S Kuduk N Yu C Raab TH Rushmore CB Frederick MG Bock T Prueksaritanont 2008 CYP2C75-Involved Autoinduction of Metabolism in Rhesus Monkeys of MK-0686, a Bradykinin B1 Receptor Antagonist J Pharmacol Exp Ther 325 935 46 1:CAS:528: DC%2BD1cXmsVOrt7c%3D 18310472
66. WH Grossman BSA SJ S Diamond MR Wright JE Grace MX Qian K He K Yeleswaram DD Christ 2004 The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: Model characterization and application Drug Metab Dispos 32 1359 69 15333515
67. H Wong JE Grace MR Wright MR Browning SJ Grossman SA Bai DD Christ 2006 Glucuronidation in the chimpanzee (Pan troglodytes): Studies with acetaminophen, oestradiol and morphine Xenobiotica 36 1178 90 1:CAS:528:DC%2BD2sXhs1Kkug%3D%3D 17162465
68. ET Williams KR Schouest M Leyk HW Strobel 2007 The chimpanzee cytochrome P450 3A subfamily: Is our closest related species really that similar? Comp Biochem Physiol D-Genom & Proteom 2 91 100
69. RS Obach 2009 Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances Curr Opin Drug Discov Devel 12 81 9 1:CAS:528:DC%2BD1MXnt12ltLw%3D 19152216
70. LM Almond J Yang M Jamei GT Tucker A Rostami-Hodjegan 2009 Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction Curr Drug Metab 10 4 420 32 1:CAS:528:DC%2BD1MXotlWku7w%3D 19519348
71. Y Ohno A Hisaka M Ueno H Suzuki 2008 General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information Clin Pharmacokinet 47 10 669 80 1:CAS:528:DC%2BD1cXhtlaitrvJ 18783297
72. M Kato K Chiba M Horikawa Y Sugiyama 2005 The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes Drug Metab Pharmacokinet 20 236 43 1:CAS:528: DC%2BD2MXhtFWitrnJ 16141603
73. L Xing Y Hu Y Lai 2009 Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions AAPS J 11 406 13 1:CAS:528:DC%2BD1MXhsFGmtbfI 19495992
74. P Chandra KL Brouwer 2004 The complexities of hepatic drug transport: current knowledge and emerging concepts Pharm Res 21 719 35 1:CAS:528: DC%2BD2cXjs1KisrY%3D 15180326
75. N Li Y Zhang F Hua Y Lai 2009 Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human Drug Metab Dispos 37 66 73 1:CAS:528:DC%2BD1MXhsVSmsQ%3D%3D 18832477
76. M Ninomiya K Ito T Horie 2005 Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2 Drug Metab Dispos 33 225 32 1:CAS:528:DC%2BD2MXht1Cjsbk%3D 15507541
77. H Tahara M Shono H Kusuhara H Kinoshita E Fuse A Takadate M Otagiri Y Sugiyama 2005 Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney Pharm Res 22 647 60 1:CAS:528:DC%2BD2MXjsFahur4%3D 15846473
78. C Timchalk 2004 Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. Evidence that the dog is not a relevant species for evaluation of human health risk Toxicology 200 1 19 1:CAS:528:DC%2BD2cXkt1aksLs%3D 15158559
79. M Hasegawa H Kusuhara H Endou Y Sugiyama 2003 Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat J Pharmacol Exp Ther 305 1087 97 1:CAS:528: DC%2BD3sXkt1Sntrs%3D 12660303
80. S Khamdang M Takeda M Shimoda R Noshiro S Narikawa XL Huang A Enomoto P Piyachaturawat H Endou 2004 Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine J Pharmacol Sci 94 197 202 1:CAS:528:DC%2BD2cXhvVCgt7w%3D 14978359
81. L Zhang Y Zhang SM Huang 2009 Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions Mol Pharm 6 1766 74 1:CAS:528:DC%2BD1MXhtl2qurjF 19839641
82. CJ Endres MG Endres JD Unadkat 2009 Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? Mol Pharm 6 1756 65 1:CAS:528:DC%2BD1MXhtl2qur7K 19886641
83. LZ Benet 2009 The drug transporter-metabolism alliance: uncovering and defining the interplay Mol Pharm 6 1631 43 1:CAS:528:DC%2BD1MXhtlyhtL7J 19874004
84. Y Shitara Y Sugiyama 2006 Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 71 105 1:CAS:528: DC%2BD28XptFCit7g%3D 16714062
85. D Pal AK Mitra 2006 MDR-and CYP3A4-mediated drug-drug interactions J Neuroimmune Pharmacol 1 323 39 18040809
86. JL Lam H Okochi Y Huang LZ Benet 2006 In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay Drug Metab Dispos 34 1336 44 1:CAS:528:DC%2BD28Xnslakurk%3D 16698890
87. EG Schuetz K Yasuda K Arimori JD Schuetz 1998 Human MDR1 and mouse mdr1 P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene Arch Biochem Biophys 350 340 7 1:CAS:528:DyaK1cXhtVWgsbs%3D 9473310
88. H Sun Y Huang L Frassetto LZ Benet 2004 Effects of uremic toxins on hepatic uptake and metabolism of erythromycin Drug Metab Dispos 32 1239 46 1:CAS:528:DC%2BD2cXovFCktb8%3D 15286055
89. CS Ernest SD Hall DR Jones 2005 Mechanism-based inactivation of CYP3A by HIV protease inhibitors J Pharmacol Exp Ther 312 583 91 1:CAS:528: DC%2BD2MXhsVCnsb0%3D 15523003
90. A Ogasawara M Utoh K Nii A Ueda T Yoshikawa T Kume K Fukuzaki 2009 Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys Drug Metab Dispos 37 122 8 1:CAS:528:DC%2BD1MXhsVSlsg%3D%3D 18854378
91. S Kumar K Samuel R Subramanian MP Braun RA Stearns SL Chiu DC Evans TA Baillie 2002 Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide J Pharmacol Exp Ther 303 969 78 1:CAS:528:DC%2BD38Xptlamt7Y%3D 12438516
92. T Prueksaritanont C Li Y Kuo C Tang K Strong-Basalyga B Carr 2006 Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of Diclofenac in rhesus monkeys Drug Metab Dispos 34 1806 10 1:CAS:528:DC%2BD28XhtFGqt7jO 16928785
93. SV Mandlekar AV Rose G Cornelius B Sleczka C Caporuscio J Wang PH Marathe 2007 Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates Xenobiotica 37 923 42 1:CAS:528: DC%2BD2sXhtVOrtbrE 17896322
94. 2-receptor antagonists: relationship between intrinsic potency and effective plasmaconcentrations Clin Pharmacokinet 20 218 36 1:CAS:528: DyaK3MXlt1Kjtb4%3D 1673880
95. N Inotsume M Nishimura M Nakano S Fujiyama T Sato 1990 The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers J Clin Pharmacol 30 50 6 1:STN:280:DyaK3c7lsVektQ%3D%3D 2303581
96. JH Lin LE Los EH Ulm DE Duggan 1988 Kinetic studies on the competition between famotidine and cimetidine in rats. Evidence of multiple renal secretory systems for organic cations Drug Metab Dispos 16 52 6 1:CAS:528: DyaL1cXhtVGqsLg%3D 2894955
97. H Tahara H Kusuhara H Endou H Koepsell T Imaoka E Fuse Y Sugiyama 2005 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters J Pharmacol Exp Ther 315 337 45 1:CAS:528:DC%2BD2MXhtVOks7vF 16006492
98. H Tahara H Kusuhara M Chida E Fuse Y Sugiyama 2006 Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists J Pharmacol Exp Ther 316 1187 94 1:CAS:528:DC%2BD28Xit1akurk%3D 16291876
99. LG Gisclon RA Boyd RL Williams KM Giacomini 1989 The effect of probenecid on the renal elimination of cimetidine Clin Pharmacol Ther 45 444 52 1:CAS:528:DyaL1MXit1Gjsb4%3D 2702802
100. 3 antagonist in animals Xenobiotica 34 1059 74 1:CAS:528:DC%2BD2MXhtVShsrc%3D 15801548
101. T Matsubara HJ Kim M Miyata M Shimada K Nagata Y Yamazoe 2004 Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat J Pharmacol Exp Ther 309 1282 90 1:CAS:528:DC%2BD2cXksFCntbs%3D 15004215
102. M Shou R Norcross G Sandig P Lu Y Li Y Lin Q Mei AD Rodrigues TH Rushmore 2003 Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450 Drug Metab Dispos 31 1161 9 1:CAS:528: DC%2BD3sXmslKlu7o%3D 12920172
103. H Wang JD Cheng D Montgomery KC Cheng 2009 Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13 Biochem Pharmacol 78 406 13 1:CAS:528:DC%2BD1MXnsFOitLc%3D 19406108